Miguel Gonzalez Velez, Medical Oncologist at John Theurer Cancer Center, Hackensack University Medical Center, shared a post on X:
” ‘The problem of plenty’ Good for patients, harder for oncology groups.
Now we have zongertinib, sevabertinib, T-DXd and more coming soon.
Upcoming questions will be sequencing and differences between HER2 mutations, amplifications and expressions.”
ASCO Living Guideline 2026.3.0 Updates Treatment Roadmap for Stage IV NSCLC With Driver Alterations
